STK31 regulates the proliferation and cell cycle of lung cancer cells via the Wnt/β‑catenin pathway and feedback regulation by c‑myc

Xiong,Jie; Xing,Shigang; Dong,Zheng; Niu,Lei; Xu,Qinghua; Liu,Pingyi; Yang,Peixia

doi:10.3892/or.2019.7441

STK31 regulates the proliferation and cell cycle of lung cancer cells via the Wnt/β‑catenin pathway and feedback regulation by c‑myc

Authors:
- Jie Xiong
- Shigang Xing
- Zheng Dong
- Lei Niu
- Qinghua Xu
- Pingyi Liu
- Peixia Yang
View Affiliations

Affiliations: Department of Respiratory, Linyi Central Hospital, Yishui, Shandong 276400, P.R. China, Department of Laboratory, Linyi Central Hospital, Yishui, Shandong 276400, P.R. China
Published online on: December 19, 2019 https://doi.org/10.3892/or.2019.7441
Pages: 395-404
Copyright: © Xiong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer, which is a leading cause of cancer‑related deaths, is diagnosed at a male to female ratio of 2.1:1. Serine‑threonine kinase 31 (STK31) is a novel cancer/testis (CT)‑related gene that is highly expressed in several types of cancers, such as lung and colorectal cancer, and plays crucial roles in cancer. In the present study, increased expression of STK31 and β‑catenin was observed in lung cancer tissues and cell lines. Downregulation of STK31 expression in lung cancer cells significantly inhibited their proliferation by arresting the cell cycle in the G1 phase concurrent with decreased β‑catenin, c‑myc and cyclin D1 protein levels, while upregulation of STK31 had the opposite effects. In addition, STK31‑induced lung cancer cell viability, proliferation, cell cycle progression, and expression of related genes were completely attenuated by a Wnt/β‑catenin inhibitor (XAV939). Similar to XAV939, a c‑myc inhibitor (10058‑F4) also significantly attenuated STK31‑induced proliferation and cell cycle progression in lung cancer cells. Inhibiting c‑myc and TRRAP significantly decreased the expression of STK31, and a chromatin immunoprecipitation (ChIP) assay confirmed that c‑myc directly bound to the STK31 promoter. These results indicated that STK31 may act as an oncogene in lung cancer and that c‑myc may be the transcription factor that promotes STK31 expression. Moreover, the results suggested that c‑myc can also regulate STK31 expression in a positive feedback loop, and the downregulation of STK31 in lung cancer cells had an inhibitory effect on cell viability, cell proliferation and cell cycle progression, likely by inactivating the Wnt/β‑catenin pathway and positive feedback regulation by c‑myc.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Shin H, Bray F and Forman D: Cancer incidence and mortality worldwide: IARC cancer base no. 10. Int J Cancer J Int Du Cancer. 136:E359–E386. 2015. View Article : Google Scholar
3	Bray F, Jemal A, Grey N, Ferlay J and Forman D: Global cancer transitions according to the human development index (2008–2030): A population-based study. Lancet Oncol. 13:790–801. 2012. View Article : Google Scholar : PubMed/NCBI
4	Hoffman PC, Mauer AM and Vokes EE: Lung cancer. Lancet. 355:479–485. 2000. View Article : Google Scholar : PubMed/NCBI
5	Fucito LM, Czabafy S, Hendricks PS, Kotsen C, Richardson D and Toll BA; Association for the Treatment of Tobacco Use and Dependence/Society for Research on Nicotine and Tobacco Synergy Committee, : Pairing smoking-cessation services with lung cancer screening: A clinical guideline from the association for the treatment of tobacco use and dependence and the society for research on nicotine and tobacco. Cancer. 122:1150–1159. 2016. View Article : Google Scholar : PubMed/NCBI
6	Youlden DR, Cramb SM and Baade PD: The international epidemiology of lung cancer: Geographical distribution and secular trends. J Thorac Oncol. 3:819–831. 2008. View Article : Google Scholar : PubMed/NCBI
7	Peifer M and Polakis P: Wnt signaling in oncogenesis and embryogenesis-A look outside the nucleus. Science. 287:1606–1609. 2000. View Article : Google Scholar : PubMed/NCBI
8	Dihlmann S and von Knebel Doeberitz M: Wnt/β-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer. 113:515–524. 2005. View Article : Google Scholar : PubMed/NCBI
9	He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LTD, Morin PJ, Vogelstein B and Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science. 281:1509–1512. 1998. View Article : Google Scholar : PubMed/NCBI
10	Tetsu O and Mccormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 398:422–426. 1999. View Article : Google Scholar : PubMed/NCBI
11	Polakis P: Wnt signaling and cancer. Genes Dev. 14:1837–1851. 2000.PubMed/NCBI
12	Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D and Rabbani SA: Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: Potential pathogenetic and prognostic implications. Cancer. 101:1345–1356. 2004. View Article : Google Scholar : PubMed/NCBI
13	Zhang WM, Lo Muzio L, Rubini C and Yan G: Effect of WNT-1 on β-catenin expression and its relation to Ki-67 and tumor differentiation in oral squamous cell carcinoma. Oncol Rep. 13:1095–1099. 2005.PubMed/NCBI
14	Nguyen DX, Chiang AC, Zhang XHF, Kim JY, Kris MG, Ladanyi M, Gerald WL and Massagu J: WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell. 138:51–62. 2009. View Article : Google Scholar : PubMed/NCBI
15	Baselga J: Targeting tyrosine kinases in cancer: The second wave. Science. 312:1175–1178. 2006. View Article : Google Scholar : PubMed/NCBI
16	Krause DS and Van Etten RA: Tyrosine kinases as targets for cancer therapy. N Engl J Med. 353:172–187. 2005. View Article : Google Scholar : PubMed/NCBI
17	Kuo PL, Huang YL, Hsieh CC, Lee JC, Lin BW and Hung LY: STK31 is a cell cycle regulated protein that contributes to the tumorigenicity of epithelial cancer cells. PLoS One. 9:e933032014. View Article : Google Scholar : PubMed/NCBI
18	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
19	Zhong L, Liu J, Hu Y, Wang W, Xu F, Xu W, Han J and Biskup E: STK31 as novel biomarker of metastatic potential and tumorigenicity of colorectal cancer. Oncotarget. 8:24354–24361. 2017.PubMed/NCBI
20	Watany MM, Elmashad NM, Badawi R and Hawash N: Serum FBLN1 and STK31 as biomarkers of colorectal cancer and their ability to noninvasively differentiate colorectal cancer from benign polyps. Clin Chim Acta. 483:151–155. 2018. View Article : Google Scholar : PubMed/NCBI
21	Hong JY, Kang B, Kim A, Hwang S, Ahn J, Lee S, Kim J, Park JH and Cheon DS: Development of a highly sensitive real-time one step RT-PCR combined complementary locked primer technology and conjugated minor groove binder probe. Virol J. 8:330. 2011. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
24	Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nature Med. 10:789–799. 2004. View Article : Google Scholar : PubMed/NCBI
25	Lim JH, Park JW and Chun YS: Human arrest defective 1 acetylates and activates β-Catenin, promoting lung cancer cell proliferation. Cancer Res. 66:106772006. View Article : Google Scholar : PubMed/NCBI
26	Bouchard C, Dittrich O, Kiermaier A, Dohmann K, Menkel A, Eilers M and Lüscher B: Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev. 15:2042–2047. 2001. View Article : Google Scholar : PubMed/NCBI
27	Bhattacharya S and Ghosh MK: HAUSP regulates c-MYC expression via de-ubiquitination of TRRAP. Cell Oncol (Dordr). 38:265–277. 2015. View Article : Google Scholar : PubMed/NCBI
28	Gu J, Gong Y, Huang M, Lu C, Spitz MR and Wu X: Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians. Carcinogenesis. 28:350–355. 2007. View Article : Google Scholar : PubMed/NCBI
29	Li H, Lei DS, Wang XQ, Skog S and He Q: Serum thymidine kinase 1 (STK1) is a prognostic and monitoring factor in patients with non-small-cell lung cancer. Oncol Rep. 13:145–149. 2005.PubMed/NCBI
30	Carretero J, Medina PP, Pio R, Montuenga LM and Sanchez-Cespedes M: Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene. 23:4037–4040. 2004. View Article : Google Scholar : PubMed/NCBI
31	Gill RK, Yang SH, Meerzaman D, Mechanic LE, Bowman ED, Jeon HS, Roy Chowdhuri S, Shakoori A, Dracheva T, Hong KM, et al: Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene. 30:3784–3791. 2011. View Article : Google Scholar : PubMed/NCBI
32	Li Z, Zhu W, Xiong L, Yu X, Chen X and Lin Q: Role of high expression levels of STK39 in the growth, migration and invasion of non-small cell type lung cancer cells. Oncotarget. 7:61366–61377. 2016.PubMed/NCBI
33	Gao Y, Song C, Hui L, Li CY, Wang J, Tian Y, Han X, Chen Y, Tian DL, Qiu X and Wang E: Overexpression of RNF146 in non-small cell lung cancer enhances proliferation and invasion of tumors through the Wnt/β-catenin signaling pathway. PLoS One. 9:e853772014. View Article : Google Scholar : PubMed/NCBI
34	Wan L, Zhang L, Fan K, Cheng ZX, Sun QC and Wang JJ: Circular RNA-ITCH suppresses lung cancer proliferation via inhibiting the Wnt/β-catenin pathway. Biomed Res Int. 2016:15794902016. View Article : Google Scholar : PubMed/NCBI
35	Miller DM, Thomas SD, Islam A, Muench D and Sedoris K: c-Myc and cancer metabolism. Clin Cancer Res. 18:5546–5553. 2012. View Article : Google Scholar : PubMed/NCBI
36	Hall M and Peters G: Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 68:67–108. 1996. View Article : Google Scholar : PubMed/NCBI
37	Lukas J, Bartkova J, Rohde M, Strauss M and Bartek J: Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol. 15:2600–2611. 1995. View Article : Google Scholar : PubMed/NCBI
38	You Z, Saims D, Chen S, Zhang Z, Guttridge DC, Guan KL, Macdougald OA, Brown AM, Evan G, Kitajewski J and Wang CY: Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol. 157:429–440. 2002. View Article : Google Scholar : PubMed/NCBI